Alembic Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 30, 2025, 10:00 am

Quick Insight

Alembic Ltd, a realty industry player, currently trades at a price of 105 with a market capitalization of 2,699 Cr. The stock's P/E ratio stands at 8.53, indicating a reasonable valuation, while the ROE and ROCE are at 13.7% and 6.90% respectively, reflecting decent returns. The company's OPM is robust at 45%, with a net profit of 311 Cr. Promoter holding is high at 70.88%, providing stability. However, institutional ownership by FIIs and DIIs is relatively low. With a healthy ICR of 100.70x and a low P/BV ratio of 0.98x, Alembic Ltd appears to be in a sound financial position, making it potentially attractive for long-term investors.

Competitors of Alembic Ltd

All Competitor Stocks of Alembic Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:05 pm

Below is a detailed analysis of the quarterly data for Alembic Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 50.00 Cr., marking a decrease of 10.00 Cr..
• For Expenses, as of Jun 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 33.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 3.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 7.00 Cr..
• For OPM %, as of Jun 2025, the value is 39.00%. The value appears to be declining and may need further review. It has decreased from 45.00% (Mar 2025) to 39.00%, marking a decrease of 6.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 7.00 Cr..
• For Tax %, as of Jun 2025, the value is 10.00%. The value appears to be improving (decreasing) as expected. It has decreased from 12.00% (Mar 2025) to 10.00%, marking a decrease of 2.00%.
• For Net Profit, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 6.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.40. The value appears to be declining and may need further review. It has decreased from 2.67 (Mar 2025) to 2.40, marking a decrease of 0.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:20 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 4:26 pm

Below is a detailed analysis of the balance sheet data for Alembic Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 51.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,287.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,134.00 Cr. (Mar 2024) to 2,287.00 Cr., marking an increase of 153.00 Cr..
• For Borrowings, as of Mar 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 9.00 Cr. (Mar 2024) to 14.00 Cr., marking an increase of 5.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 150.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 134.00 Cr. (Mar 2024) to 150.00 Cr., marking an increase of 16.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,503.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,329.00 Cr. (Mar 2024) to 2,503.00 Cr., marking an increase of 174.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 409.00 Cr.. The value appears strong and on an upward trend. It has increased from 369.00 Cr. (Mar 2024) to 409.00 Cr., marking an increase of 40.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 1,900.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,786.00 Cr. (Mar 2024) to 1,900.00 Cr., marking an increase of 114.00 Cr..
• For Other Assets, as of Mar 2025, the value is 194.00 Cr.. The value appears strong and on an upward trend. It has increased from 173.00 Cr. (Mar 2024) to 194.00 Cr., marking an increase of 21.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,503.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,329.00 Cr. (Mar 2024) to 2,503.00 Cr., marking an increase of 174.00 Cr..

Notably, the Reserves (2,287.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Alembic Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 10.46. This value is within the healthy range. It has increased from 7.42 (Mar 23) to 10.46, marking an increase of 3.04.
• For Diluted EPS (Rs.), as of Mar 24, the value is 10.46. This value is within the healthy range. It has increased from 7.42 (Mar 23) to 10.46, marking an increase of 3.04.
• For Cash EPS (Rs.), as of Mar 24, the value is 3.92. This value is within the healthy range. It has increased from 3.40 (Mar 23) to 3.92, marking an increase of 0.52.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.11. It has increased from 80.93 (Mar 23) to 85.11, marking an increase of 4.18.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.11. It has increased from 80.93 (Mar 23) to 85.11, marking an increase of 4.18.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 6.13. It has increased from 4.96 (Mar 23) to 6.13, marking an increase of 1.17.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 4.35. This value is within the healthy range. It has increased from 4.07 (Mar 23) to 4.35, marking an increase of 0.28.
• For PBIT / Share (Rs.), as of Mar 24, the value is 4.04. This value is within the healthy range. It has increased from 3.81 (Mar 23) to 4.04, marking an increase of 0.23.
• For PBT / Share (Rs.), as of Mar 24, the value is 4.00. This value is within the healthy range. It has increased from 3.38 (Mar 23) to 4.00, marking an increase of 0.62.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 3.62. This value is within the healthy range. It has increased from 3.14 (Mar 23) to 3.62, marking an increase of 0.48.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 10.46. This value is within the healthy range. It has increased from 7.42 (Mar 23) to 10.46, marking an increase of 3.04.
• For PBDIT Margin (%), as of Mar 24, the value is 70.88. This value is within the healthy range. It has decreased from 82.20 (Mar 23) to 70.88, marking a decrease of 11.32.
• For PBIT Margin (%), as of Mar 24, the value is 65.90. This value exceeds the healthy maximum of 20. It has decreased from 76.91 (Mar 23) to 65.90, marking a decrease of 11.01.
• For PBT Margin (%), as of Mar 24, the value is 65.20. This value is within the healthy range. It has decreased from 68.21 (Mar 23) to 65.20, marking a decrease of 3.01.
• For Net Profit Margin (%), as of Mar 24, the value is 58.96. This value exceeds the healthy maximum of 10. It has decreased from 63.35 (Mar 23) to 58.96, marking a decrease of 4.39.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 170.56. This value exceeds the healthy maximum of 20. It has increased from 149.83 (Mar 23) to 170.56, marking an increase of 20.73.
• For Return on Networth / Equity (%), as of Mar 24, the value is 12.29. This value is below the healthy minimum of 15. It has increased from 9.17 (Mar 23) to 12.29, marking an increase of 3.12.
• For Return on Capital Employeed (%), as of Mar 24, the value is 4.63. This value is below the healthy minimum of 10. It has increased from 4.61 (Mar 23) to 4.63, marking an increase of 0.02.
• For Return On Assets (%), as of Mar 24, the value is 11.53. This value is within the healthy range. It has increased from 8.64 (Mar 23) to 11.53, marking an increase of 2.89.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.06. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 24, the value is 1.52. This value is within the healthy range. It has decreased from 2.05 (Mar 23) to 1.52, marking a decrease of 0.53.
• For Quick Ratio (X), as of Mar 24, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 23) to 0.49, marking a decrease of 0.50.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.09. This value is below the healthy minimum of 4. It has increased from 0.07 (Mar 23) to 0.09, marking an increase of 0.02.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 21.03. This value is within the healthy range. It has decreased from 24.24 (Mar 23) to 21.03, marking a decrease of 3.21.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 20.43. This value is within the healthy range. It has decreased from 23.41 (Mar 23) to 20.43, marking a decrease of 2.98.
• For Earning Retention Ratio (%), as of Mar 24, the value is 78.97. This value exceeds the healthy maximum of 70. It has increased from 75.76 (Mar 23) to 78.97, marking an increase of 3.21.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 79.57. This value exceeds the healthy maximum of 70. It has increased from 76.59 (Mar 23) to 79.57, marking an increase of 2.98.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 100.70. This value is within the healthy range. It has decreased from 224.79 (Mar 23) to 100.70, marking a decrease of 124.09.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 84.77. This value is within the healthy range. It has decreased from 197.06 (Mar 23) to 84.77, marking a decrease of 112.29.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,154.92. It has increased from 1,520.56 (Mar 23) to 2,154.92, marking an increase of 634.36.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 11.95 (Mar 23) to 13.68, marking an increase of 1.73.
• For EV / EBITDA (X), as of Mar 24, the value is 19.30. This value exceeds the healthy maximum of 15. It has increased from 14.54 (Mar 23) to 19.30, marking an increase of 4.76.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 13.64. This value exceeds the healthy maximum of 3. It has increased from 11.97 (Mar 23) to 13.64, marking an increase of 1.67.
• For Retention Ratios (%), as of Mar 24, the value is 78.96. This value exceeds the healthy maximum of 70. It has increased from 75.75 (Mar 23) to 78.96, marking an increase of 3.21.
• For Price / BV (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 23) to 0.98, marking an increase of 0.25.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 13.64. This value exceeds the healthy maximum of 3. It has increased from 11.97 (Mar 23) to 13.64, marking an increase of 1.67.
• For EarningsYield, as of Mar 24, the value is 0.12. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.12.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness